Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00502541 | Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema | PHASE2 | COMPLETED | 196 | — | — | Sep 1, 2001 | Sep 1, 2006 | Nov 28, 2013 | - | — |
| Arm | Type | Description |
|---|---|---|
| Fluocinolone acetonide | EXPERIMENTAL | Fluocinolone acetonide intravitreal implant |
| Standard of Care | ACTIVE_COMPARATOR | Standard of care |
| Name | Type | Description |
|---|---|---|
| fluocinolone acetonide | DRUG | fluocinolone acetonide 0.59 mg intravitreal implant |
| Standard of Care | PROCEDURE | Repeat macular grid laser or observation |
Inclusion Criteria: * Males and nonpregnant females at least 18 years of age, with DME in the study eye * Edema must involve fixation and be at least 1 disc area in size * Visual acuity of ≥20 and ≤68 letters by ETDRS in the study eye * The study eye must have received at least one macular laser tr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901, Aflibercept |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Oculis Holding AG | OCS | 2 | PHASE3 | Dexamethasone, Vehicle |
| AbbVie, Inc. | ABBV | 3 | PHASE2 | ABBV-RGX-314 Dose 1, Steroid, Aflibercept |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | bevacizumab |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 IVT, Aflibercept IVT |
| Alvotech | ALVO | 1 | PHASE3 | AVT29, Eylea HD |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | — | ADVM-022 |